BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024

Rhea-AI Summary

BridgeBio Pharma (Nasdaq: BBIO) announced that additional data from its Phase 3 ATTRibute-CM study of acoramidis in ATTR-CM will be presented at two major conferences. At the ESC Congress 2024 in London (Aug 30 - Sep 2), Dr. Mathew S. Maurer will present a moderated poster on the increase in serum TTR levels observed with acoramidis treatment. At the HFSA Annual Scientific Meeting 2024 in Atlanta (Sep 27-30), Dr. Daniel P. Judge will give an oral presentation on how acoramidis improves clinical outcomes in ATTR-CM patients, based on a post hoc recurrent event analysis. These presentations aim to provide further insights into the efficacy of acoramidis in treating transthyretin amyloid cardiomyopathy.

Positive

• Additional Phase 3 data on acoramidis to be presented at two major cardiology conferences
• Presentations focus on improved clinical outcomes and increased serum TTR levels with acoramidis treatment
• Data suggests potential efficacy of acoramidis in treating ATTR-CM

Negative

• None.

PALO ALTO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced today that additional data on clinical outcomes from ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be presented at the European Society of Cardiology (ESC) Congress 2024, taking place in London, United Kingdom on August 30 – September 2, 2024 and the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024, taking place in Atlanta, Georgia on September 27 - 30, 2024.

ESC Moderated Poster details:

Increase in Serum TTR Levels Observed with Acoramidis Treatment in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Insights From ATTRibute-CM and Its Open-Label Extension
Session Title: Cardiac amyloidosis: diagnosis and outcomes
Presenter: Dr. Mathew S. Maurer, Columbia University Irving Medical Center, New York, United States of America
Date/time: Friday, August 30 at 10:00 am ET
Location: Station 10 - Research Gateway

HFSA Oral Presentation details:

Acoramidis Improves Clinical Outcomes in Patients with Transthyretin Amyloid Cardiomyopathy: A Post Hoc Recurrent Event Analysis of ATTRibute-CM
Session Title: Oral Abstract Sessions
Presenter: Dr. Daniel P. Judge, Medical University of South Carolina, United States of America and Co-Chair of the ATTRibute-CM Steering Committee
Date/time: Saturday, September 28 at 4:36 pm ET
Location: Oral Abstract Stage | Exhibit Hall

The presentations will be available following the sessions on the Presentations page within the Investors section of the BridgeBio website at https://investor.bridgebio.com.

About BridgeBio Pharma, Inc.
BridgeBio Pharma (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015, and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter and Facebook.

BridgeBio Contact:
Vikram Bali
contact@bridgebio.com
(650)-789-8220

FAQ

What is the purpose of BridgeBio's Phase 3 ATTRibute-CM trial for BBIO stock?

The Phase 3 ATTRibute-CM trial evaluates the efficacy of acoramidis in treating transthyretin amyloid cardiomyopathy (ATTR-CM). Positive results could significantly impact BBIO's stock by demonstrating the potential of acoramidis as a treatment for ATTR-CM.

When and where will BridgeBio (BBIO) present new data from the ATTRibute-CM trial in 2024?

BridgeBio will present new data from the ATTRibute-CM trial at two conferences in 2024: the ESC Congress in London from August 30 to September 2, and the HFSA Annual Scientific Meeting in Atlanta from September 27 to 30.

What specific results will be presented about acoramidis at the ESC Congress 2024 for BBIO?

At the ESC Congress 2024, Dr. Mathew S. Maurer will present data on the increase in serum TTR levels observed with acoramidis treatment in patients with ATTR-CM, based on insights from the ATTRibute-CM trial and its open-label extension.

What will be discussed in the HFSA 2024 presentation about BridgeBio's (BBIO) acoramidis?

At the HFSA 2024 meeting, Dr. Daniel P. Judge will present a post hoc recurrent event analysis from the ATTRibute-CM trial, showing how acoramidis improves clinical outcomes in patients with transthyretin amyloid cardiomyopathy.